A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL Birch 300 IR in Children and Adolescents 5 to 17 yo With Birch Pollen-induced Allergic Rhinoconjunctivitis w/o Asthma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Birch pollen allergy immunotherapy (Primary)
Indications Allergic rhinoconjunctivitis
Focus Registrational; Therapeutic Use
Acronyms YOBI
Sponsors Stallergenes Greer plc

Most Recent Events

16 Apr 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health
16 Apr 2024 Planned End Date changed from 30 Jul 2024 to 30 Nov 2025.
16 Apr 2024 Planned primary completion date changed from 31 May 2024 to 31 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight